卡莫司他

卡莫司他
臨床資料
商品名（英語：Drug nomenclature）	Foipan
AHFS/Drugs.com	國際藥品名稱
給藥途徑	Oral
ATC碼	B02AB04 (WHO) ;
法律規範狀態
法律規範	美：Not FDA approved; 處方藥（℞-only）;
識別資訊
	IUPAC命名法 N,N-Dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)phenylacetate; ;
CAS號	59721-28-7
PubChem CID	2536;
IUPHAR/BPS	6432;
ChemSpider	2440 ;
UNII	0FD207WKDU;
ChEMBL	ChEMBL590799 ;
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID6044010 ;
化學資訊
化學式	C20H22N4O5
摩爾質量	398.42 g·mol−1
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES CN(C)C(=O)COC(=O)CC1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C(N)N;
	InChI InChI=1S/C20H22N4O5/c1-24(2)17(25)12-28-18(26)11-13-3-9-16(10-4-13)29-19(27)14-5-7-15(8-6-14)23-20(21)22/h3-10H,11-12H2,1-2H3,(H4,21,22,23) ; Key:XASIMHXSUQUHLV-UHFFFAOYSA-N ;

卡莫司他（英語：camostat，開發代碼FOY-305），是一種絲氨酸蛋白酶抑制劑，在體內有各種功能。被用來治療某些腫瘤，並被用來有效地抵抗病毒感染。還可抑制肝臟纖維化、腎病或胰腺炎。^[1]^[2]^[3]^[4]^[5]在日本被批准使用。^[6] 2020年德國科學家在細胞雜誌上發表論文指出甲磺酸卡莫司他（英語：camostat mesylate）積極對抗TMPRSS2，部分阻斷SARS-2-S-驅動的進入Caco-2和Vero195 TMPRSS2細胞。^[7]

來源

^ Okuno, M.; Kojima, S.; Akita, K.; Matsushima-Nishiwaki, R.; Adachi, S.; Sano, T.; Takano, Y.; Takai, K.; Obora, A.; Yasuda, I.; Shiratori, Y.; Okano, Y.; Shimada, J.; Suzuki, Y.; Muto, Y.; Moriwaki, Y. Retinoids in liver fibrosis and cancer. Frontiers in Bioscience. 2002, 7 (4): d204–18. PMID 11779708. doi:10.2741/A775.
^ Hsieh, H. P.; Hsu, J. T. Strategies of development of antiviral agents directed against influenza virus replication. Current Pharmaceutical Design. 2007, 13 (34): 3531–42. PMID 18220789. doi:10.2174/138161207782794248.
^ Kitamura, K.; Tomita, K. Proteolytic activation of the epithelial sodium channel and therapeutic application of a serine protease inhibitor for the treatment of salt-sensitive hypertension. Clinical and Experimental Nephrology. 2012, 16 (1): 44–8. PMID 22038264. doi:10.1007/s10157-011-0506-1.
^ Zhou, Y.; Vedantham, P.; Lu, K.; Agudelo, J.; Carrion Jr, R.; Nunneley, J. W.; Barnard, D.; Pöhlmann, S.; McKerrow, J. H.; Renslo, A. R.; Simmons, G. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Research. 2015, 116: 76–84. PMC 4774534 . PMID 25666761. doi:10.1016/j.antiviral.2015.01.011.
^ Ueda, M.; Uchimura, K.; Narita, Y.; Miyasato, Y.; Mizumoto, T.; Morinaga, J.; Hayata, M.; Kakizoe, Y.; Adachi, M.; Miyoshi, T.; Shiraishi, N.; Kadowaki, D.; Sakai, Y.; Mukoyama, M.; Kitamura, K. The serine protease inhibitor camostat mesilate attenuates the progression of chronic kidney disease through its antioxidant effects. Nephron. 2015, 129 (3): 223–32. PMID 25766432. doi:10.1159/000375308.
^ Camostat. drugs.com. [2020-03-02]. （原始內容存檔於2020-03-05）.
^ SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically-proven protease inhibitor. [2020-03-05]. （原始內容存檔於2021-02-24）.

[1] Okuno, M.; Kojima, S.; Akita, K.; Matsushima-Nishiwaki, R.; Adachi, S.; Sano, T.; Takano, Y.; Takai, K.; Obora, A.; Yasuda, I.; Shiratori, Y.; Okano, Y.; Shimada, J.; Suzuki, Y.; Muto, Y.; Moriwaki, Y. Retinoids in liver fibrosis and cancer. Frontiers in Bioscience. 2002, 7 (4): d204–18. PMID 11779708. doi:10.2741/A775.

[2] Hsieh, H. P.; Hsu, J. T. Strategies of development of antiviral agents directed against influenza virus replication. Current Pharmaceutical Design. 2007, 13 (34): 3531–42. PMID 18220789. doi:10.2174/138161207782794248.

[3] Kitamura, K.; Tomita, K. Proteolytic activation of the epithelial sodium channel and therapeutic application of a serine protease inhibitor for the treatment of salt-sensitive hypertension. Clinical and Experimental Nephrology. 2012, 16 (1): 44–8. PMID 22038264. doi:10.1007/s10157-011-0506-1.

[4] Zhou, Y.; Vedantham, P.; Lu, K.; Agudelo, J.; Carrion Jr, R.; Nunneley, J. W.; Barnard, D.; Pöhlmann, S.; McKerrow, J. H.; Renslo, A. R.; Simmons, G. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Research. 2015, 116: 76–84. PMC 4774534 . PMID 25666761. doi:10.1016/j.antiviral.2015.01.011.

[5] Ueda, M.; Uchimura, K.; Narita, Y.; Miyasato, Y.; Mizumoto, T.; Morinaga, J.; Hayata, M.; Kakizoe, Y.; Adachi, M.; Miyoshi, T.; Shiraishi, N.; Kadowaki, D.; Sakai, Y.; Mukoyama, M.; Kitamura, K. The serine protease inhibitor camostat mesilate attenuates the progression of chronic kidney disease through its antioxidant effects. Nephron. 2015, 129 (3): 223–32. PMID 25766432. doi:10.1159/000375308.

[6] Camostat. drugs.com. [2020-03-02]. （原始內容存檔於2020-03-05）.

[7] SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically-proven protease inhibitor. [2020-03-05]. （原始內容存檔於2021-02-24）.

[1]

[2]

[3]

[4]

[5]

[6]

[7]